1. Correale, M, Paolillo, S, Mercurio, V, et al. Comorbidities in chronic heart failure: An update from Italian Society of Cardiology (SIC) Working Group on Heart Failure. Eur J Intern Med 2020; 71: 23–31.
Google Scholar | Crossref | Medline2. Groenveld, HF, Januzzi, JL, Damman, K, et al. Anemia and mortality in heart failure patients a systematic review and meta-analysis. J Am Coll Cardiol 2008; 52: 818–827.
Google Scholar | Crossref | Medline | ISI3. Tang, YD, Katz, SD. Anemia in chronic heart failure: Prevalence, etiology, clinical correlates, and treatment options. Circulation 2006; 113: 2454–2461.
Google Scholar | Crossref | Medline | ISI4. Agostoni, P, Salvioni, E, Debenedetti, C, et al. Relationship of resting hemoglobin concentration to peak oxygen uptake in heart failure patients. Am J Hematol 2010; 85: 414–417.
Google Scholar | Medline | ISI5. Berry, C, Poppe, KK, Gamble, GD, et al. Prognostic significance of anaemia in patients with heart failure with preserved and reduced ejection fraction: Results from the MAGGIC individual patient data meta-analysis. QJM 2016; 109: 377–382.
Google Scholar | Crossref | Medline6. Agostoni, P, Corra, U, Cattadori, G, et al. Metabolic exercise test data combined with cardiac and kidney indexes, the MECKI score: A multiparametric approach to heart failure prognosis. Int J Cardiol 2013; 167: 2710–2718.
Google Scholar | Crossref | Medline | ISI7. Von Haehling, S, Jankowska, EA, van Veldhuisen, DJ, et al. Iron deficiency and cardiovascular disease. Nat Rev Cardiol 2015; 12: 659–669.
Google Scholar | Crossref | Medline8. Dinatolo, E, Dasseni, N, Metra, M, Lombardi, C, et al. Iron deficiency in heart failure. J Cardiovasc Med (Hagerstown) 2018; 19: 706–716.
Google Scholar | Crossref | Medline9. Jankowska, EA, Rozentryt, P, Witkowska, A, et al. Iron deficiency predicts impaired exercise capacity in patients with systolic chronic heart failure. J Card Fail 2011; 17: 899–906.
Google Scholar | Crossref | Medline | ISI10. Magri, D, de Martino, F, Moscucci, F, et al. Anemia and iron deficiency in heart failure: Clinical and prognostic role. Heart Fail Clin 2019; 15: 359–369.
Google Scholar | Crossref | Medline11. Cattadori, G, Agostoni, P, Corra, U, et al. Heart failure and anemia: Effects on prognostic variables. Eur J Intern Med 2017; 37: 56–63.
Google Scholar | Crossref | Medline12. Swedberg, K, Young, JB, Anand, IS, et al. Treatment of anemia with darbepoetin alfa in systolic heart failure. N Engl J Med 2013; 368: 1210–1219.
Google Scholar | Crossref | Medline | ISI13. Lewis, GD, Malhotra, R, Hernandez, AF, et al. Effect of oral iron repletion on exercise capacity in patients with heart failure with reduced ejection fraction and iron deficiency: The IRONOUT HF randomized clinical trial. JAMA 2017; 317: 1958–1966.
Google Scholar | Crossref | Medline14. Ambrosy, AP, Lewis, GD, Malhotra, R, et al. Identifying responders to oral iron supplementation in heart failure with a reduced ejection fraction: A post-hoc analysis of the IRONOUT-HF trial. J Cardiovasc Med (Hagerstown) 2019; 20: 223–225.
Google Scholar | Crossref | Medline15. Anker, SD, Comin Colet, J, Filippatos, G, et al. Ferric carboxymaltose in patients with heart failure and iron deficiency. N Engl J Med 2009; 361: 2436–2448.
Google Scholar | Crossref | Medline | ISI16. Ponikowski, P, van Veldhuisen, DJ, Comin-Colet, J, et al. Beneficial effects of long-term intravenous iron therapy with ferric carboxymaltose in patients with symptomatic heart failure and iron deficiency. Eur Heart J 2015; 36: 657–668.
Google Scholar | Crossref | Medline17. Okonko, DO, Grzeslo, A, Witkowski, T, et al. Effect of intravenous iron sucrose on exercise tolerance in anemic and nonanemic patients with symptomatic chronic heart failure and iron deficiency FERRIC-HF: A randomized, controlled, observer-blinded trial. J Am Coll Cardiol 2008; 51: 103–112.
Google Scholar | Crossref | Medline | ISI18. Van Veldhuisen, DJ, Ponikowski, P, van der Meer, P, et al. Effect of ferric carboxymaltose on exercise capacity in patients with chronic heart failure and iron deficiency. Circulation 2017; 136: 1374–1383.
Google Scholar | Crossref | Medline19. Ponikowski, P, Voors, AA, Anker, SD, et al 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur J Heart Fail 2016; 18: 891–975.
Google Scholar | Crossref | Medline | ISI20. McHugh, K, DeVore, AD, Wu, J, et al. Heart failure with preserved ejection fraction and diabetes: JACC State-of-the-Art Review. J Am Coll Cardiol 2019; 73: 602–611.
Google Scholar | Crossref | Medline21. Solang, L, Malmberg, K, Ryden, L. Diabetes mellitus and congestive heart failure. Further knowledge needed. Eur Heart J 1999; 20: 789–795.
Google Scholar | Crossref | Medline | ISI22. Gohar, A, Kievit, RF, Valstar, GB, et al. Opportunistic screening models for high-risk men and women to detect diastolic dysfunction and heart failure with preserved ejection fraction in the community. Eur J Prev Cardiol 2019; 26: 613–623.
Google Scholar | SAGE Journals | ISI23. Pavlovic, A, Polovina, M, Ristic, A, et al. Long-term mortality is increased in patients with undetected prediabetes and type-2 diabetes hospitalized for worsening heart failure and reduced ejection fraction. Eur J Prev Cardiol 2019; 26: 72–82.
Google Scholar | SAGE Journals | ISI24. Kannel, WB, McGee, DL. Diabetes and cardiovascular disease. The Framingham study. JAMA 1979; 241: 2035–2038.
Google Scholar | Crossref | Medline | ISI25. Johansson, I, Edner, M, Dahlstrom, U, et al. Is the prognosis in patients with diabetes and heart failure a matter of unsatisfactory management? An observational study from the Swedish Heart Failure Registry. Eur J Heart Fail 2014; 16: 409–418.
Google Scholar | Crossref | Medline26. Cavender, MA, Steg, PG, Smith, SC, et al. Impact of diabetes mellitus on hospitalization for heart failure, cardiovascular events, and death: Outcomes at 4 years from the Reduction of Atherothrombosis for Continued Health (REACH) Registry. Circulation 2015; 132: 923–931.
Google Scholar | Crossref | Medline | ISI27. Paolillo, S, Salvioni, E, Perrone Filardi, P, et al. Long-term prognostic role of diabetes mellitus and glycemic control in heart failure patients with reduced ejection fraction: Insights from the MECKI Score database. Int J Cardiol 2020; 317: 103–110.
Google Scholar28. Paolillo, S, Marsico, F, Prastaro, M, et al. Diabetic cardiomyopathy: Definition, Diagnosis, and therapeutic implications. Heart Fail Clin 2019; 15: 341–347.
Google Scholar | Crossref | Medline29. Cosentino, F, Grant, PJ, Aboyans, V, et al. 2019 ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD. Eur Heart J 2020; 41: 255–323.
Google Scholar | Crossref | Medline30. Rorth, R, Jhund, PS, Kristensen, SL, et al. The prognostic value of troponin T and N-terminal pro B-type natriuretic peptide, alone and in combination, in heart failure patients with and without diabetes. Eur J Heart Fail 2019; 21: 40–49.
Google Scholar | Crossref | Medline31. Seferovic, PM, Petrie, MC, Filippatos, GS, et al. Type 2 diabetes mellitus and heart failure: A position statement from the Heart Failure Association of the European Society of Cardiology. Eur J Heart Fail 2018; 20: 853–872.
Google Scholar | Crossref | Medline32. Scalvini, S, Grossetti, F, Paganoni, AM, et al. Impact of in-hospital cardiac rehabilitation on mortality and readmissions in heart failure: A population study in Lombardy, Italy, from 2005 to 2012. Eur J Prev Cardiol 2019; 26: 808–817.
Google Scholar | SAGE Journals | ISI33. Cunha, FM, Pereira, J, Marques, P, et al. Diabetic patients need higher furosemide doses: A report on acute and chronic heart failure patients. J Cardiovasc Med (Hagerstown) 2020; 21: 21–26.
Google Scholar | Crossref | Medline34. Kemps, H, Krankel, N, Dorr, M, et al. Exercise training for patients with type 2 diabetes and cardiovascular disease: What to pursue and how to do it. A Position Paper of the European Association of Preventive Cardiology (EAPC). Eur J Prev Cardiol 2019; 26: 709–727.
Google Scholar | SAGE Journals | ISI35. McMurray, JJV, DeMets, DL, Inzucchi, SE, et al. A trial to evaluate the effect of the sodium-glucose co-transporter 2 inhibitor dapagliflozin on morbidity and mortality in patients with heart failure and reduced left ventricular ejection fraction (DAPA-HF). Eur J Heart Fail 2019; 21: 665–675.
Google Scholar | Crossref | Medline36. Packer M, Anker SD, Butler J, et al.; on behalf of the EMPEROR-Reduced Trial Investigators. Cardiovascular and Renal Outcomes With Empagliflozin in Heart Failure. N Engl J Med. Epub ahead of print 29 August 2020. DOI: 10.1056/NEJMoa2022190.
Google Scholar37. Solomon, SD, Jhund, PS, Claggett, BL, et al. Effect of dapagliflozin in patients with HFrEF treated with sacubitril/valsartan: The DAPA-HF trial. JACC Heart Fail. Epub ahead of print 8 July 2020. DOI: 10.1016/j.jchf.2020.04.008.
Google Scholar38. Maisel, WH, Stevenson, LW. Atrial fibrillation in heart failure: Epidemiology, pathophysiology, and rationale for therapy. Am J Cardiol 2003; 91: 2D–8D.
Google Scholar | Crossref | Medline | ISI39. Agostoni, P, Emdin, M, Corra, U, et al. Permanent atrial fibrillation affects exercise capacity in chronic heart failure patients. Eur Heart J 2008; 29: 2367–2372.
Google Scholar | Crossref | Medline | ISI40. Palermo, P, Magri, D, Sciomer, S, et al. Delayed anaerobic threshold in heart failure patients with atrial fibrillation. J Cardiopulm Rehabil Prev 2016; 36: 174–179.
Google Scholar | Crossref | Medline41. Magri, D, Agostoni, P, Corra, U, et al. Deceptive meaning of oxygen uptake measured at the anaerobic threshold in patients with systolic heart failure and atrial fibrillation. Eur J Prev Cardiol 2015; 22: 1046–1055.
Google Scholar | SAGE Journals | ISI42. Paolillo, S, Agostoni, P, Masarone, D, et al. Prognostic role of atrial fibrillation in patients affected by chronic heart failure. Data from the MECKI score research group. Eur J Intern Med 2015; 26: 515–520.
Google Scholar | Crossref | Medline43. Campodonico, J, Piepoli, M, Clemenza, F, et al. Dose-dependent efficacy of beta-blocker in patients with chronic heart failure and atrial fibrillation. Int J Cardiol 2018; 273:141–146.
Google Scholar | Crossref | Medline